DDS (Drug Delivery System) is a technology developed to deliver active drug substance specifically to the target at the right time or right amount, thus increasing efficacy and reducing side effects of the drug substance. DDS is usually developed for those drugs that have toxicity that could harm normal cells and tissues or that lack stability that could be destroyed before they are delivered to the target.
  Peptron's DDS technology relates to "sustained release (SR)" formulations where a precise amount of the drug substance is slowly released at the right time. This is convenient for patients who must be administered the same drug substance every hour, day, or week. Usually, SR formulations are designed to release drug substance for durations of weeks or even months.
  Bioactive peptides or proteins such as insulin, calcitonin, LHRH analogs, and somatostatin analogs that have minimal side effects and high efficacy are being developed into drugs. However, these drug substances are unstable or poorly absorbed when orally administered. Therefore, in most cases, the drugs must be developed into injectable or nasal spray formulations, even in the cases where they have to be administered every hour, day, or week.
 
We have developed 1 and 3 month SR injectable formulation of LHRH analogs using PLGA, a polymer approved by the USFDA and being used to produce various pharmaceutical products. Peptron's focus is to develop and introduce various peptide and protein drugs in SR injectable formulations in the future.
 
1) Specialized in peptide and protein drug delivery, particularly in injectable sustained release formulations
  2) Extensive experience in basic studies on peptides and proteins such as synthesis of peptides and peptide-conjugates, production of antibodies against peptides, purification and characterization of peptides and proteins, evaluation of structure-activity inter-relations of proteins
  3) Variety of choices for the most suitable manufacturing method on the specific target drug after intensive studies
  4) Well organized in-house facilities for peptide and protein drug delivery research from manufacturing to in vitro/in vivo screening of the formulations